Rimegepant plus immunotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (rimegepant and a PD-1 immunotherapy) for people with colorectal cancer that has spread to the liver. It is for patients who have already tried standard chemotherapy without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that has spread to the liver and cannot be surgically removed.
- You have already tried standard chemotherapy (including drugs like 5-FU, irinotecan, oxaliplatin) and it stopped working or caused too many side effects.
- You are in generally good health (able to care for yourself, with a life expectancy of at least 3 months).
- You have not had prior treatment with a PD-1 immunotherapy drug or an mTOR inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the combination of everolimus (a targeted pill) with a PD-1 immunotherapy drug for people with advanced colorectal cancer that has a specific gene change (PTEN mutation). The goal is to see if this two-drug approach works better than standard treatments for cancers that have stopped responding to chemotherapy.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.